<DOC>
	<DOCNO>NCT01297543</DOCNO>
	<brief_summary>Ex vivo expand human myeloid progenitor cell ( hMPCs ; CLT-008 ) potential accelerate neutrophil recovery decrease risk febrile neutropenia infection patient receive chemotherapy acute lymphoblastic leukemia ( ALL ) , acute myeloid leukemia ( AML ) , chronic myeloid leukemia ( CML ) , high-risk myelodysplasia ( MDS ) . In study , safety , tolerability activity CLT-008 administer `` standard care '' cytarabine-based consolidation induction/re-induction chemotherapy determine monitoring adverse reaction , infusion reaction , graft-versus host disease ( GVHD ) , neutrophil platelet recovery , hMPC persistence , infection complication .</brief_summary>
	<brief_title>Safety Study Human Myeloid Progenitor Cells ( CLT-008 ) After Chemotherapy Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Key Hematological malignancy , include : AML , ALL MDS Planned treatment cytarabinebased chemotherapy regimen Adequate hepatic , renal , hematologic , cardiac respiratory function Key Prior allograft history active GVHD within 3 year Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Re-induction chemotherapy</keyword>
	<keyword>Consolidation chemotherapy</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplasia</keyword>
</DOC>